Corbus Pharmaceuticals Holding Asset Resilience Ratio
Corbus Pharmaceuticals Holding asset resilience ratio. Corbus Pharmaceuticals Holding (CRBP) has an Asset Resilience Ratio of 74.47% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See CRBP cash and liquid assets coverage to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Corbus Pharmaceuticals Holding (2014–2025)
Asset resilience ratio of Corbus Pharmaceuticals Holding from 2014 to 2025. This chart shows how Corbus Pharmaceuticals Holding's Asset Resilience Ratio has changed over time. Read total liabilities of Corbus Pharmaceuticals Holding for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Corbus Pharmaceuticals Holding's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see CRBP total assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $94.57 Million | 74.47% |
| Total Liquid Assets | $94.57 Million | 74.47% |
Asset Resilience Insights
- Very High Liquidity: Corbus Pharmaceuticals Holding maintains exceptional liquid asset reserves at 74.47% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Corbus Pharmaceuticals Holding Industry Peers by Asset Resilience Ratio
Compare Corbus Pharmaceuticals Holding's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL |
Biotechnology | 62.31% |
|
Verona Pharma plc
F:I9SA |
Biotechnology | 0.00% |
|
Centessa Pharmaceuticals PLC ADR
NASDAQ:CNTA |
Biotechnology | 33.37% |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252 |
Biotechnology | 2.03% |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161 |
Biotechnology | 8.08% |
|
Bavarian Nordic
CO:BAVA |
Biotechnology | 10.83% |
|
Hebei Changshan Biochem Pharma
SHE:300255 |
Biotechnology | -0.03% |
|
Tibet Cheezheng Tibetan Medicine Co Ltd
SHE:002287 |
Biotechnology | 37.31% |
Corbus Pharmaceuticals Holding Asset Resilience Ratio by Year (2014–2025)
Corbus Pharmaceuticals Holding asset resilience ratio by year from 2014 to 2025. The table below shows the annual Asset Resilience Ratio data for Corbus Pharmaceuticals Holding.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 80.13% | $134.78 Million | $168.19 Million | -4.46pp |
| 2024-12-31 | 84.59% | $131.86 Million | $155.88 Million | +59.19pp |
| 2023-12-31 | 25.40% | $7.18 Million | $28.27 Million | -38.23pp |
| 2022-12-31 | 63.63% | $42.19 Million | $66.31 Million | -3.80pp |
| 2021-12-31 | 67.43% | $72.64 Million | $107.73 Million | -- |
| 2020-12-31 | 0.00% | $0.00 | $102.29 Million | -- |
| 2017-12-31 | 0.24% | $159.00K | $66.98 Million | -0.60pp |
| 2016-12-31 | 0.84% | $150.00K | $17.89 Million | -- |
| 2015-12-31 | 0.00% | $0.00 | $12.88 Million | -- |
| 2014-12-31 | 0.00% | $0.00 | $6.60 Million | -- |
About Corbus Pharmaceuticals Holding
Corbus Pharmaceuticals Holdings, Inc., a clinical stage company, develops and commercializes therapeutics for cancer and obesity. Its pipeline includes CRB-701, an antibody drug conjugate that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E; and CRB-913, a peripherally restricted cannabinoid type-1 receptor inverse agonist for the treat… Read more